Darolutamide with androgen deprivation therapy for metastatic hormone sensitive prostate cancer

Darolutamide with androgen deprivation therapy (ADT) is in clinical development to treat prostate cancer that is metastatic (has spread to another part of the body) and hormone-sensitive, where the cancer is controlled by lowering levels of the hormone testosterone. Prostate cancer affects the prostate (a small gland only found in men), but symptoms generally do not appear until it is large enough to affect the urethra (the tube connecting the bladder to outside the body). Only 50% of patients diagnosed with metastatic hormone sensitive prostate cancer (mHSPC) survive five years or more after diagnosis. Therefore, treatment is focused on controlling further spread and managing symptoms. Treatments for mHSPC include chemotherapy, hormone therapy and radiotherapy, but these can be associated with significant adverse side effects.